Shunqiang Li, PhD

Medical School Department Internal Medicine
Research Program Breast Cancer Research
Shunqiang Li

Researcher Background

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, WashU Medicine

Training

  • 1999 - 2002: Postdoctoral research, Fred Hutchinson Cancer Research Center, Seattle, WA
  • 2002 - 2004: Postdoctoral Research, University of North Carolina at Chapel Hill, Chapel Hill, NC

Education

  • 1999: PhD, Chinese Academy of Medical Sciences and Peking Union Medical College, P.R. China

Research & Selected Publications

Research Interest

1) Establishment and characterization of patient-derived xenograft (PDX) models, 2) PDX-based preclinical testing of new anticancer drugs and treatments, 3) Application of PDX models to cancer translation research, including tumorigenesis, resistance, metastasis, and biomarker, 4) HAMLET core service

Research Publications

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.
Authors:

Zheng ZY, Chen A, Jaehnig EJ, one or more additional authors omitted Li S, one or more additional authors omitted Chang EC

Journal & Year:

Sci Transl Med • 2025

Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer.
Authors:

Zhou S, Zhang Y, Belmar J, one or more additional authors omitted Li S, Zhu W

Journal & Year:

Cancer Res • 2025

PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model.
Authors:

Gil M, Yu T, Alderson M, one or more additional authors omitted Li S, Opyrchal M

Journal & Year:

J Natl Compr Canc Netw • 2025

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer.
Authors:

Zhang Y, Zhou S, Kai Y, one or more additional authors omitted Li S, Zhu W

Journal & Year:

Nat Commun • 2024

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.
Authors:

White BS, Woo XY, Koc S, one or more additional authors omitted Li S, one or more additional authors omitted Chuang JH

Journal & Year:

Cancer Res • 2024

Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
Authors:

Singh AK, Lewis CD, Boas CAWV, one or more additional authors omitted Li S, one or more additional authors omitted Hallahan DE

Journal & Year:

Clin Cancer Res • 2024

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Authors:

Wu Y, Chen S, Yang X, one or more additional authors omitted Li S, one or more additional authors omitted Chen F

Journal & Year:

Cancer Res • 2023

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.
Authors:

Gou X, Kim BJ, Anurag M, one or more additional authors omitted Li S, one or more additional authors omitted Ellis MJ

Journal & Year:

Cancer Res • 2023